{"entity":{"id":"nct07221253","kind":"trial","name":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)","aka":["ARTEMIDE-Biliary02"],"tldr":"A phase 3 trial of Rilvegostomig, Durvalumab and Gemcitabine + cisplatin in biliary tract cancer, run by AstraZeneca, now recruiting.","summary":"A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) is a phase 3 interventional study registered as NCT07221253 by AstraZeneca, with 1100 participants planned, started 2025-12-04 and due to reach its primary completion in 2029-07-31. Interventions recorded: Rilvegostomig, Durvalumab and Gemcitabine/Cisplatin.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07221253","url":"https://clinicaltrials.gov/study/NCT07221253"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["cholangiocarcinoma"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["rilvegostomig","durvalumab","gemcitabine-cisplatin"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07221253","phase":"3","setting":"Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02)","sponsor":"AstraZeneca","participation":[{"nct":"NCT07221253","source":"https://clinicaltrials.gov/study/NCT07221253","fetchedAt":"2026-10-07T16:55:33.599Z","studySha256":"2a858f14e161c5c33f53eac99d3f7ae83bec5a908503330c549912e1aa4c48b2","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-28","leadSponsor":"AstraZeneca","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1100,"enrolmentType":"ESTIMATED","siteCount":183,"recruitingSiteCount":153,"countries":["Australia","Belgium","Brazil","Canada","China","France","Germany","India","Italy","Japan","Netherlands","Poland","South Korea","Spain","Taiwan","Thailand","Turkey (Türkiye)","United Kingdom","United States"]}],"started":"2025-12-04","startedType":"actual","enrolled":1100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07221253/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/"},{"id":"rilvegostomig","kind":"drug","name":"Rilvegostomig","route":"/drugs/rilvegostomig/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}